FINHUB Insights

BDX · Q1 FY25 · Oct 1 – Dec 31, 2024

Becton Dickinson Q1 FY25: where the revenue came from and where it went

Becton Dickinson Q1 FY25: revenue $5.2B (+10% year over year). Net profit $0.3B. Largest cohort Medical $2.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Oct 1 – Dec 31, 2024
Reported
Feb 6, 2025 10-Q
Sankey diagram of Becton Dickinson's income statement for Q1 FY25: revenue of $5.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$5.2B +10% year over year
Gross profit$2.2B 43% margin
Operating profit$0.5B 9% margin
Net profit$0.3B 6% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Dec 31, 2024).
ItemValueShare of revenueYear over year
Revenue 5.2 100% +10%
Medical 2.6 50% +17%
Life Sciences 1.3 25% +1%
Interventional 1.3 25% +6%
Cost of revenue−2.956%
Gross profit2.243% margin+0pp
Research & development−0.37%+0pp
SG&A−1.326%+0pp
Other−0.12%+0pp
Operating profit0.59% margin−1pp
Interest & other costs−0.2
Net profit0.36%+0pp
Filing on EDGAR More quarters of BDX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters